Alcon is an American Swiss medical company specializing in eye care products with headquarters in Geneva, Switzerland, and incorporated in Fribourg, Switzerland.
Company profile
Ticker
ALC, ALC-SE, ALC-MM
Exchange
Website
CEO
David Endicott
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ALC stock data
Latest filings (excl ownership)
6-K
Alcon Publishes Agenda for 2024 Annual General Meeting
5 Apr 24
6-K
Current report (foreign)
27 Feb 24
20-F
2023 FY
Annual report (foreign)
27 Feb 24
6-K
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
27 Feb 24
6-K
Alcon Reports Third Quarter 2023 Results
14 Nov 23
6-K
Alcon Reports Second Quarter 2023 Results
15 Aug 23
SD
Conflict minerals disclosure
30 May 23
6-K
Alcon Reports First Quarter 2023 Results
9 May 23
6-K
Alcon Publishes Agenda for 2023 Annual General Meeting
29 Mar 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
27 Feb 23
Transcripts
ALC
Earnings call transcript
2022 Q3
16 Nov 22
ALC
Earnings call transcript
2022 Q2
10 Aug 22
ALC
Earnings call transcript
2022 Q1
11 May 22
ALC
Earnings call transcript
2021 Q2
18 Aug 21
ALC
Earnings call transcript
2021 Q1
5 May 21
ALC
Earnings call transcript
2020 Q4
24 Feb 21
ALC
Earnings call transcript
2020 Q3
11 Nov 20
Latest ownership filings
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
144
Notice of proposed sale of securities
29 Feb 24
SC 13G
UBS ASSET MANAGEMENT AMERICAS INC
13 Feb 24
SC 13G/A
BlackRock Inc.
1 Feb 24
144
Notice of proposed sale of securities
21 Aug 23
144
Notice of proposed sale of securities
16 May 23
144
Notice of proposed sale of securities
11 May 23
144
Notice of proposed sale of securities
11 May 23
SC 13G
BlackRock Inc.
23 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
43.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 577 |
Opened positions | 66 |
Closed positions | 61 |
Increased positions | 182 |
Reduced positions | 189 |
13F shares | Current |
---|---|
Total value | 16.60 tn |
Total shares | 215.33 mm |
Total puts | 1.87 mm |
Total calls | 2.53 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 18.24 mm | $1.41 tn |
Credit Suisse | 14.83 mm | $1.14 tn |
Aristotle Capital Management | 12.94 mm | $997.53 bn |
Clearbridge Advisors | 9.56 mm | $736.71 bn |
Harding Loevner | 8.93 mm | $687.82 bn |
Zurcher Kantonalbank | 8.89 mm | $689.46 bn |
Vontobel Holding | 7.86 mm | $609.27 bn |
Ako Capital | 6.52 mm | $502.34 bn |
T. Rowe Price Investment Management | 6.36 mm | $489.68 bn |
Wellington Management | 6.32 mm | $490.02 bn |
News
Stifel Maintains Buy on Alcon, Maintains $95 Price Target
22 Apr 24
Goldman Sachs Initiates Coverage On Alcon with Buy Rating, Announces Price Target of $100
10 Apr 24
Stifel Reiterates Buy on Alcon, Maintains $95 Price Target
13 Mar 24
Argus Research Maintains Buy on Alcon, Raises Price Target to $100
4 Mar 24
Piper Sandler Maintains Buy on Alcon, Raises Price Target to $100
1 Mar 24